ISSUE 7/2026

BDMAI BULLETIN

From the Desk of President

Dear Friends,

Greetings from BDMAI.

Over the past three months, your Association has remained actively engaged in representing the interests of the Indian bulk drug industry and responding to the evolving regulatory and business environment. Our efforts have been focused on addressing operational challenges faced by members.

One of the significant initiatives during this period was the interactive session organised jointly with the ONDLS team of CDSCO. The programme witnessed overwhelming participation from the industry and provided members with an opportunity to obtain first-hand clarifications on the implementation of the ONDLS portal and related regulatory procedures. The encouraging feedback received from participants reinforces the importance of continuous engagement between regulators and industry, and BDMAI will continue to facilitate such interactions.

The Association has also pursued several representations with Central and State Government authorities on issues affecting the bulk drug sector. We are pleased that our follow-up with the Andhra Pradesh Drug Control Administration resulted in the clearance of pending applications of member companies, demonstrating the value of constructive dialogue with the Government. We sincerely appreciate the prompt response extended by the authorities.

As global supply chains continue to evolve, access to timely and credible market intelligence is becoming increasingly important. Beginning with this edition, BDMAI is expanding its market intelligence initiatives by introducing structured analysis of India's bulk drug trade, covering import and export trends, key markets, major products, trade policy developments and emerging opportunities. Over the coming months, we intend to build a comprehensive trade intelligence database based on official Government statistics, enabling our members to monitor market trends, identify export opportunities and make data-driven business decisions.

Together, let us continue to strengthen India's position as a trusted global supplier of quality bulk drugs and pharmaceutical intermediates.

With Warm Regards

Ch A P Rameswara Rao
National President

In this Bulletin you can expect

Summary:

The global pharmaceutical sector continued to witness unprecedented activity during June–July 2026, with multinational companies pursuing strategic acquisitions, billion-dollar licensing agreements, and accelerated innovation across oncology, obesity, respiratory diseases, gene therapies, and rare diseases. The month also saw continued momentum in China's biotechnology ecosystem, increased outsourcing to India, and regulatory reforms aimed at simplifying market access and pricing.

Major themes during the month include:

- Oncology remained the largest area of investment.
- Antibody Drug Conjugates (ADCs) continue to dominate oncology pipelines.
- GLP-1 therapies continue reshaping diabetes and obesity treatment.
- Chinese biotechnology companies are emerging as preferred innovation partners for global pharmaceutical companies.
- India continues strengthening its position as a preferred global manufacturing and CDMO destination.
- Regulatory agencies continue emphasizing data integrity, digital quality systems, and supply chain resilience.

Global Mergers, Acquisitions & Strategic Collaborations

Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals

Deal Value: US$10 Billion

Vertex announced the acquisition of Crinetics Pharmaceuticals, marking one of the largest pharmaceutical transactions of 2026. The acquisition expands Vertex's presence into endocrinology, adding approved and late-stage therapies for acromegaly and congenital adrenal hyperplasia, while diversifying beyond cystic fibrosis.

AstraZeneca partners with Sino Biopharmaceutical

Deal Value: Up to US$1.9 Billion

AstraZeneca obtained global rights (excluding China) to develop and commercialize TQC3721, a respiratory drug candidate, through a major licensing agreement with Sino Biopharmaceutical. The collaboration reflects growing global confidence in Chinese pharmaceutical innovation.

Sino Biopharmaceutical expands partnership with GSK

Sino Biopharmaceutical also secured exclusive commercialization rights in mainland China for GSK's respiratory products Trelegy Ellipta and Anoro Ellipta, further strengthening multinational collaborations in the Chinese market.

Novartis strengthens ADC portfolio

Novartis agreed to acquire Myricx Bio, a UK biotechnology company developing next-generation antibody-drug conjugates (ADCs), reinforcing its precision oncology strategy.

Sun Pharma acquires Innovcare Life Sciences

Sun Pharmaceutical Industries acquired Innovcare Life Sciences Pvt Ltd, Mumbai at USD 28.7 million expanding nutracuetical and specialty healthcare portfolio.

Zudus completed acquisistion of Assertio Holding, USA

Zydus Lifesciences acquired Assertio Holdings Inc, USA at US$ 166.4 million, which provides zydus with a strong commercial footprint in the US specialty pharmaceutical market and access to established branded products

Aurobindo Pharma acquires Lannett Company LCC

Aurobindo Pharma received FTC clearance to acquired Lannett Company LLC at US$ 250 million. The acquisition significantly stenghts Aurobindo’s US generic medicines business and manufacturing capabilities.

Drug Development & Clinical Pipeline

Oncology remains the innovation leader

Several important clinical developments were reported during the month:

- Roche reported encouraging Phase III data for Divarasib in KRAS-mutated lung cancer.
- Abivax reported positive late-stage results for Obefazimod in ulcerative colitis, increasing expectations of a potential acquisition.
- Investment in ADC technology continues to accelerate across major pharmaceutical companies.

Obesity medicines continue global expansion

GLP-1 receptor agonists remain the fastest-growing pharmaceutical segment worldwide. Companies continue investing heavily in oral formulations, manufacturing capacity, and peptide API production to meet rapidly increasing demand.

Rare disease therapies attract significant investment

Rare diseases continue to receive strong investment due to regulatory incentives, premium pricing, and accelerated approval pathways, driving acquisitions and licensing activity.

Regulatory Intelligence

Date	Drug (Generic/Brand)	Company	Indication	Regulatory Authority	Importance
17 Jun 2026	Utebzi (Tebipenem pivoxil)	GSK / Spero Therapeutics	Complicated urinary tract infections (cUTI)	**US FDA**	**First oral carbapenem antibiotic approved in the U.S.**, providing an important option for multidrug-resistant urinary tract infections and reducing the need for hospitalization.
12 Jun 2026	Ambelvist (Gadoquatrane)	Bayer	MRI contrast agent	**US FDA**	Next-generation gadolinium contrast agent offering high-quality imaging at a lower gadolinium dose, potentially improving patient safety.
19 Jun 2026	Etcamah (Camizestrant)	AstraZeneca	ER-positive/HER2-negative advanced breast cancer	**EMA**	New endocrine therapy for hormone receptor-positive breast cancer, expanding treatment options for patients with endocrine-resistant disease.
19 Jun 2026	Cenrifki (Tolebrutinib)	Sanofi	Multiple Sclerosis	**EMA**	First BTK inhibitor approved in Europe for

Date	Drug (Generic/Brand)	Company	Indication	Regulatory Authority	Importance
					selected multiple sclerosis patients, representing an important advance in neuroimmunology.
June 2026	Milsaperidone (Bysanti)	Otsuka	Schizophrenia	**PMDA (Japan)**	New antipsychotic providing an additional therapeutic option with a differentiated pharmacological profile.
June 2026	Lumvoa (Veligrotug)	Immunovant/Roche*	Thyroid eye disease	**PMDA (Japan)**	Expands biologic treatment options for thyroid eye disease, reflecting continued innovation in autoimmune disorders.

MHRA (United Kingdom)

During the review period, the **MHRA** did not issue any widely reported approvals of major new molecular entities comparable to those above. Most activities involved line extensions, manufacturing variations, and pharmacovigilance updates rather than landmark new-drug authorizations.

NMPA (China)

The **NMPA** continued to approve innovative domestic oncology and immunology products during June 2026. Several approvals involved Chinese-developed therapies and label expansions, underscoring China's growing role in pharmaceutical innovation. For a monthly bulletin, this section is best presented with the most commercially significant approvals after reviewing the official monthly NMPA release.

Manufacturing trends

Global investments continue in Peptide manufacturing, High-potency APIs, Continuous manufacturing, Cell and gene therapy production, Antibody-drug conjugates, Digital manufacturing

ASSOCIATION ACTIVITIES

During June and the beginning of July 2026, BDMAI continued to actively represent the interests of the bulk drug industry before various Government departments and regulatory authorities while organizing knowledge-sharing programmes and disseminating important policy updates to its members.

Regulatory Advocacy

WHO GMP / CoPP through ONDLS Portal

- Organized an interaction between the industry and the C-DAC team on **19 June 2026** to discuss practical issues being faced in obtaining WHO GMP Certificates and CoPPs through the ONDLS portal.

- Continued follow-up with CDSCO and C-DAC to simplify the digital application process and resolve operational bottlenecks.

Tapentadol under NDPS Act

- Alerted members regarding the proposal to bring **Tapentadol** under the provisions of the NDPS Act, enabling companies to assess the regulatory implications and prepare for possible compliance requirements.

Recommended Amendments to NDPS Act

- Submitted recommendations for amendment of NDPS Act and subsequently actively participated in the review meeting on the same subject organized by Department of Revenue, Government of India.

Industry Development & Investment Facilitation

Land Availability for API Industries

- Circulated information regarding availability of industrial land at **Orvakal Industrial Area, Kurnool (Andhra Pradesh)** to facilitate expansion and new investments by API manufacturers.
- Promoted Andhra Pradesh as an emerging destination for bulk drug manufacturing investments.

Unified Consent & Authorization Management System (UCAMS)

- Encouraged member participation in CPCB's demonstration and consultation session on the Unified Consent & Authorization Management System (UCAMS), helping industries prepare for digital environmental approvals.

ASSOCIATION ACTIVITIES

Conferences & Member Capacity Building

Future of API Conference

- Promoted participation in the conference **"Innovate – Sustain – Evolve: Future of API"** held on **3 July 2026** at Hotel Avasa, Hyderabad.
- Negotiated special registration benefits for BDMAI members to encourage wider industry participation.

Environment, Safety & Sustainability Industrial Fire & Safety Seminar

BDMAI circulated information about an important event organized by CEP, where following topics were covered:

- Industrial Fire & Safety
- Digital Water Accounting
- Pharmaceuticals in the Environment

The programme focused on improving safety standards, environmental compliance and sustainable manufacturing practices across the API sector.

Export Promotion

IPHEX 2026 Recommended ember participation in **IPHEX 2026**, India's premier pharmaceutical export exhibition, highlighting opportunities to expand exports and strengthen global business partnerships.

Trade & Policy Updates

BDMAI regularly disseminated important Government notifications, including:

- Anti-dumping duty developments relating to **Beta Naphthol (2-Naphthol)** imports from China.
- Various trade facilitation measures affecting the pharmaceutical and chemical sectors.
- Updates on logistics, customs and export-related policy initiatives relevant to API manufacturers.

Member Services

- Introduced consultancy support on commercial matters such as **DGFT, GST, SEZ and EOU issues** through an external consultancy arrangement for the benefit of member companies.

- Continued dissemination of regulatory updates, technical guidance and industry notifications through circulars.

COMMERCIAL ARTICLE

Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

The success of GLP-1 medicines has changed the way healthcare professionals view obesity and metabolic diseases. Over the past few years, drugs such as semaglutide and tirzepatide have shown that significant weight loss can be achieved through medication, offering new hope for millions of people living with obesity. As demand for these treatments continues to grow, pharmaceutical companies are now working on the next generation of GLP-1 therapies that aim to deliver even greater benefits.

These new treatments are designed not only to help patients lose weight but also to improve overall health, reduce side effects, and provide more convenient dosing options. As a result, next-generation GLP-1 therapies have become one of the most closely watched areas in the pharmaceutical industry.

Understanding GLP-1 Therapy

GLP-1, or glucagon-like peptide-1, is a natural hormone produced in the intestine after eating. It helps regulate blood sugar levels, slows stomach emptying, and sends signals to the brain that create a feeling of fullness.

GLP-1 medicines work by mimicking the action of this hormone. Patients often eat less, feel satisfied for longer periods, and experience gradual weight loss. Many of these drugs were initially developed for type 2 diabetes before researchers discovered their strong impact on body weight.

The success of current GLP-1 therapies has led researchers to explore new ways of improving their effectiveness.

What Makes Next-Generation Therapies Different?

The next wave of obesity treatments is moving beyond traditional GLP-1 drugs. Researchers are developing medicines that target multiple biological pathways at the same time.

Some experimental therapies combine GLP-1 activity with other hormones involved in appetite control and energy balance. By targeting several pathways, these treatments may help patients achieve greater weight loss while maintaining muscle mass and improving metabolic health.

Many companies are also working on oral medicines that could replace injections. While weekly injections have proven effective, some patients prefer the convenience of a daily pill. Oral therapies could make obesity treatment more accessible and improve long-term patient adherence.

Focus on More than Weight Loss

One of the most important developments in next-generation GLP-1 research is the growing focus on overall health outcomes.
Researchers are studying how these therapies affect heart disease, kidney disease, liver conditions, and other obesity-related complications. Early findings suggest that some GLP-1-based treatments may offer benefits beyond weight management.

This broader approach reflects a changing view of obesity. Instead of treating obesity as a lifestyle issue, healthcare providers increasingly recognize it as a chronic disease that affects multiple organs and systems throughout the body.

Pharmaceutical Companies Race to Innovate

The commercial success of existing GLP-1 medicines has sparked intense competition among pharmaceutical companies. Major drug manufacturers and biotechnology firms are investing billions of dollars in obesity research programs.

Numerous drug candidates are currently being evaluated in clinical trials. Some are investigating combination therapies, while others are developing entirely new approaches to metabolic disease treatment.

This competitive environment is accelerating innovation and creating opportunities for new therapies to enter the market over the next several years.

Challenges Facing the Market

Despite the excitement, several challenges remain. Manufacturing capacity continues to be a major concern as demand for obesity medications grows worldwide. Supply shortages have affected access to some treatments, highlighting the need for expanded production capabilities.

Cost is another important issue. Many obesity medicines remain expensive, and insurance coverage varies significantly across different countries and healthcare systems. Improving affordability will be essential if these therapies are to reach a larger patient population.
Researchers are also working to better understand the long-term effects of treatment. While current data are encouraging, additional studies will help determine how these medicines perform over many years of use.

The Future of Obesity Care

The next generation of GLP-1 therapies represents one of the most significant developments in modern medicine. Scientists are no longer focused solely on helping patients lose weight.

Instead, they are working to create treatments that improve overall metabolic health and reduce the risk of serious diseases associated with obesity.

As more candidates enter clinical trials and new data become available, the obesity treatment landscape is expected to evolve rapidly. Improved effectiveness, greater convenience, and broader health benefits could make next-generation GLP-1 therapies an important part of healthcare for years to come.

For patients, healthcare providers, and the pharmaceutical industry, these advances signal a future where obesity can be managed more effectively than ever before. The coming decade may ultimately redefine how metabolic diseases are treated and how long-term health outcomes are improved across global populations.

Source: Pharma Journalist

TECHNICAL ARTICLE

Balancing Circular Solvent Recovery to Lower Carbon Emissions and Minimize Material Waste

POSTED ON BY WUDBOX

Introduction

The global nutraceutical industry is experiencing unprecedented growth, driven by a consumer base prioritizing proactive health, clean labels, and botanical efficacy. However, high-purity extraction demands massive quantities of organic solvents. As commercial scale expands, traditional linear "take-make-dispose" solvent models impose severe operational costs and conflict with modern environmental mandates, demanding aggressive manufacturing decarbonisation.

Adopting a circular solvent architecture allows organizations to transition from legacy disposal paradigms into highly optimized, low-carbon closed-loop systems. This strategic transition directly addresses the dual challenges of raw material volatility and strict Scope 1, 2, and 3 carbon accounting, converting regulatory compliance pressures into measurable competitive advantages.

The Operational Bottleneck: Carbon and Linear Solvent Challenges

In high-throughput botanical extraction and purification, solvents such as ethanol, isopropyl alcohol, hexane, and ethyl acetate act as primary vehicles for isolating bioactive compounds. Under a conventional linear framework, these chemicals follow a high-emissions, high-risk trajectory:

- **Upstream Volatility:** Procurement costs fluctuate due to volatile crude oil markets, which also carry heavy fossil-fuel manufacturing footprints. Every barrel of virgin solvent purchased carries a legacy of Scope 3 supply chain carbon.
- **Downstream Liabilities:** Spent solvents are categorized as hazardous waste, requiring specialized third-party transport and energy-intensive incineration. This creates ongoing liability, regulatory documentation burdens, and logistical vulnerabilities.
- **Scope 3 Emissions:** Off-site thermal destruction of chemical waste and the ongoing production of replacement virgin chemicals significantly expands an organization's Scope 3 greenhouse gas footprint, frustrating corporate sustainability commitments.

Strategic Insight: Incinerating one metric ton of spent mixed solvents releases approximately 2.5 to 3.1 metric tons of CO_2 equivalent into the atmosphere. On-site decarbonization prevents this thermal release completely, preserving the base molecules for continuous operational reuse.

TECHNICAL ARTICLE

The Paradigm Shift: Low-Carbon Circular Solvent Systems

Circular solvent recovery captures spent effluents at the point of discharge and purifies them back to production-grade specifications. By integrating advanced separation technologies, organizations replace fossil fuel-intensive waste loops with a low-carbon recycling framework that processes identical chemical volumes hundreds of times. This shifts the chemical supply paradigm from an ongoing raw consumable to a permanent, circular manufacturing asset.

Key Separation Technologies and Mechanics

The transition to a highly resilient circular recovery network relies on a combination of specific separation engineering systems tailored to organic extraction lines:

- **Fractional Distillation Columns:** These multi-stage systems separate complex solvent streams based on boiling point differentials under automated thermal control. This maximizes column efficiency, enabling the recovery of multi-component mixtures down to ultra-pure fractions.

- **Pervaporation Membrane Units:** By utilizing non-porous polymeric or ceramic membranes, pervaporation breaks water-solvent azeotropes via selective molecular permeation. Operating below boiling points, it bypasses traditional distillation thermal limits, driving down Scope 2 electricity consumption.

- **Low-Temperature Vacuum Evaporation:** Reducing system pressure lowers the boiling thresholds of target chemicals. This enables rapid solvent vaporization with minimal thermal energy expenditure while entirely protecting heat-sensitive botanical compounds from degradation.

Quantifying Environmental and Decarbonization Advantages

Transitioning to closed-loop recovery directly drives manufacturing decarbonization across all levels of environmental accounting. By regenerating solvents on-site, a company eliminates the emissions associated with manufacturing virgin chemicals and trucking hazardous waste to distant disposal facilities.

The environmental and carbon impacts can be measured across three main areas:

1. **Scope 1 Reductions:** Deploying energy-efficient, electric-driven pervaporation or vapor compression systems minimizes direct stationary combustion emissions compared to traditional fossil-fueled thermal oxidizers. This allows facilities to eliminate localized flue-gas emissions.

2. **Scope 3 Mitigation:** Avoiding the purchase of fossil-derived chemicals removes upstream manufacturing emissions from the corporate ledger. It also eliminates thousands of miles of heavy-duty waste transportation hauling over public roads.

3. **Resource Conservation:** Minimizing raw material extraction preserves water and feedstock resources, advancing corporate water stewardship and ecosystem protection goals alongside strict carbon reduction targets.

Cutting Costs and Saving Resources

While the decarbonization benefits are compelling, the financial returns of circular recovery are equally strong. On-site recovery transforms solvent procurement from a continuous operational expense into a predictable, capitalized asset model that proves low-carbon manufacturing is highly profitable.

The primary economic and carbon drivers include:

- **Reduced Purchase Requirements:** Achieving a 95% solvent recovery rate decreases virgin chemical purchasing by up to 90%, insulating operations from commodity market shocks and embedded supply chain carbon.
- **Lower Waste Management Costs:** Minimizing hazardous waste volumes significantly reduces regulatory compliance costs, specialized logistics fees, and carbon emissions from waste logistics.
- **Improved Unit Economics:** Lowering the cost-per-kilogram of finished nutraceutical extracts expands gross margins across major product lines while strengthening green brand equity in a competitive consumer market.
- **Tax and Regulatory Shields:** Proactively lowering volatile organic compound (VOC) emissions and hazardous waste output shields operations from future carbon taxes, disposal penalties, and rising environmental compliance levies.

Strategic Impact Matrix

Operational Metric	Linear Baseline (Per Annum)	Circular Target (Per Annum)	Net Strategic & Carbon Impact
Virgin Solvent Purchases	500,000 Liters	50,000 Liters	90% reduction in material dependency and embodied carbon
Hazardous Waste Haulage	480,000 Liters	15,000 Liters	96.8% decrease in disposal liabilities and logistical emissions
Carbon Footprint	1,450 Metric Tons	380 Metric Tons	73.7% absolute drop in carbon intensity

Supply Chain Risk Profile	High (Market Dependent)	Low (Internal Control)	Protected operational continuity with carbon resilience

Overcoming Implementation and Regulatory Hurdles

Implementing circular solvent systems requires managing technical and regulatory complexities. In the nutraceutical sector, maintaining product purity and preventing cross-contamination are critical requirements that demand strict engineering controls alongside decarbonisation efforts.

Key execution priorities include:

- **Cross-Contamination Controls:** Dedicated solvent loops should be established for distinct product families (e.g., separating allergen extracts from standard botanicals) to eliminate any risk of cross-contact.
- **Analytical Validation:** Implementing inline gas chromatography (GC) and Karl Fischer titration ensures recovered solvents meet United States Pharmacopeia (USP) or internal purity standards before re-entering extraction lines.
- **Regulatory Alignment:** Documented validation protocols must prove that recycled solvents do not introduce heavy metals, pesticide residues, or degradation byproducts into final consumer products, keeping operations fully aligned with current Good Manufacturing Practices (cGMP) without sacrificing decarbonization speed.

Strategic Execution and Next Steps

Transitioning to a circular, decarbonized solvent architecture requires a coordinated approach across engineering, finance, and sustainability teams. The following phased framework is recommended for deployment:

- **Phase 1:** Operational Audit and Carbon Baseline Map all current solvent waste streams, document chemical compositions, measure exact water contamination levels, and calculate current total expenditures alongside the baseline carbon footprint of virgin procurement and waste disposal.
- **Phase 2:** Pilot Validation Run small-scale slipstream testing using pervaporation or fractional distillation to confirm that recovered solvent purity matches the baseline requirements needed for high-yield extracts while measuring energy efficiency parameters.

- **Phase 3:** Full-Scale Integration Install automated, skid-mounted recovery systems directly into existing manufacturing lines. This minimizes plant downtime while instantly creating closed-loop recycling capabilities that immediately lower daily carbon metrics.

Conclusion: The Future of Sustainable Extraction

Integrating circular solvent recovery represents a key strategic evolution for modern manufacturing. By treating spent solvents as valuable assets rather than liabilities, companies can permanently decouple production growth from environmental impact and carbon output.

Implementing these closed-loop systems strengthens supply chain resilience, insulates operations from regulatory and market shocks, and secures a market leadership position in an increasingly eco-conscious, decarbonized global economy.

India's Bulk Drug Imports & Exports Analysis
April–May 2026 (2026-27)

Executive Summary

This analysis is based on the DGCIS Trade statistics. India's bulk drug sector commenced the Financial Year 2026-27 on a positive note, with exports registering healthy growth during the first two months of the financial year. Export performance was particularly encouraging in May 2026, reflecting sustained demand from regulated as well as emerging pharmaceutical markets.

India's bulk drug exports increased from US$747.72 million during April–May (2025-26) to US$816.01 million during April–May (2026-27), representing a growth of **9.13%**.
Monthly import figures indicate a relatively stable trend during the same period, with imports increasing marginally in April but declining during May, suggesting moderation in overseas procurement by domestic manufacturers

Export Performance:

Bulk drug exports increased from US$747.72 million to US$816.01 million during April–May 2026, registering 9.13% growth. Export momentum strengthened in May with double-digit growth.

Month	2025-26	2026-27	Growth
April	369.01	393.13	6.54%
May	378.72	422.88	11.66%
Total	747.72	816.01	9.13%

India's Bulk Drug Imports & Exports Analysis
April–May 2026 (2026-27)

Exports generated an additional **US$68.29 million** during the first two months compared with the corresponding period of the previous financial year.

A noteworthy feature is the acceleration in export growth during May, indicating strengthening international demand after a relatively moderate increase in April.

Key Highlights

- Export growth remained positive in both months.
- May recorded double-digit growth of **11.66%**.
- Export momentum improved significantly during the second month.
- Higher overseas demand contributed to increased foreign exchange earnings.

Region-wise Export Analysis

The regional distribution of exports reflects India's diversified global presence. The major destination regions continue to be:

- Europe
- North America
- Asia
- Latin America
- Africa

Among various regions, **Africa registered one of the strongest growth rates**, increasing by **34.43%** over the previous year.The regional analysis also indicates healthy growth across several emerging pharmaceutical markets, highlighting increasing acceptance of Indian active pharmaceutical ingredients (APIs) and drug intermediates.

The geographical diversification reduces dependence on any single export market and enhances resilience against regional economic uncertainties.

Major Export Destinations

The United States continues to remain India's largest export destination for bulk drugs.

India's Bulk Drug Imports & Exports Analysis
April–May 2026 (2026-27)

Top Export Markets

Country	2025-26 (US$ Mn)	2026-27 (US$ Mn)	Growth
USA	81.84	93.25	13.94%
Other destinations	48.87	62.00	26.88%
Brazil	28.20	47.76	69.33

(Other major destinations include Germany, Italy, China, Bangladesh, Spain, South Korea and Japan.)

Key Observations

- Exports recorded healthy growth in both months.
- May exports grew 11.66%, indicating stronger overseas demand.
- Monthly import figures suggest moderation in May.
- Regulated and emerging markets continued to support API exports.
- The United States retained its position as the largest export destination.
- Brazil exhibited remarkable growth, indicating expanding opportunities in Latin America.
- Demand from regulated markets remained stable despite increasing pricing pressures.

India's Bulk Drug Imports & Exports Analysis
April–May 2026 (2026-27)

Import Performance

Monthly import data indicates a mixed trend during April–May 2026.

Month	2025-26	2026-27	Growth
April	366.45	378.22	3.21%
May	387.67	365.80	-5.64%



Regional Pattern of Imports

- Regional import data indicates that Asia continues to dominate India's bulk drug imports, reflecting established supply chains for pharmaceutical intermediates and key starting materials.
- Imports from ASEAN countries recorded modest growth during the period, while imports from Africa declined sharply due to relatively small trade volumes.

The regional composition suggests that India continues to diversify sourcing while gradually strengthening domestic manufacturing capabilities.

India's Bulk Drug Imports & Exports Analysis
April–May 2026 (2026-27)

Key Observations

- Imports increased modestly during April.
- Imports declined during May.
- The decline in May may reflect:
    - improved domestic production,
    - inventory rationalisation by manufacturers,
    - reduced procurement of selected intermediates,
    - increasing availability from domestic API manufacturers.

The moderation in imports is a positive indicator from the perspective of reducing dependence on imported raw materials

Outlook

The first two months of Financial Year 2026-27 indicate a positive start for India's bulk drug sector.

Key takeaways include:

- Export growth remained robust at over **9%**.
- Export momentum strengthened during May.
- Demand from regulated markets continued to support growth.
- Imports showed signs of moderation during May.
- India's diversified export basket and expanding global footprint continue to reinforce its position as a leading supplier of pharmaceutical ingredients.

If the current momentum is sustained over the coming quarters, Financial Year 2026-27 is expected to witness another year of healthy growth in India's bulk drug exports, supported by strong manufacturing capabilities, regulatory compliance, and increasing global demand.

Special offer to BDMAI Members:

The organizers of Global Chem Show offer 30 fully built up 9 sq. meter stalls to BDMAI members **Free of Cost**. The objective of this offer is to promote participation of APIs & Intermediates, Pellets manufacturers in this show.

BDMAI's participation in this show last year was successful with 17 member companies participating in the Pavilion**.**

All members are requested to take advantage of this unique opportunity. Interested members may contact us at **info@bdmai.org**; **ed@bdmai.org**